Fiscal Year 2014 Duchenne Muscular Dystrophy Research Program Reference Table of Award Mechanisms and Submission Requirements

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|---|---|---|---|---|
| Investigator-Initiated Research Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-14-DMDRP-IIRA | Principal Investigator: Must be an Independent Investigator at or above the level of Assistant Professor (or equivalent). Optional Qualified Collaborator: Must be at or above the level of Assistant Professor (or equivalent). Optional Nested Resident or Medical Student Trainee: Resident trainee must be enrolled in an accredited residency program. Medical student trainee must be enrolled in a nationally accredited (or equivalent) medical school. Trainees must be able to devote a minimum of 40% level of effort. | Supports translational research that will have an impact on extending and improving the function, quality of life, and lifespan for all individuals diagnosed with DMD. Clinical trials are allowed. Preliminary data required. | Maximum funding of \$525,000 in direct costs (plus indirect costs) or \$675,000 in direct costs if requesting an Optional Collaborator. Nested traineeship: Additional maximum of \$75,000 for residents or \$55,000 for medical students in direct and indirect costs over a one-year period of performance. Period of performance should not exceed 3 years. | Pre-application (Preproposal): July 16, 2014 5:00 p.m. Eastern time Preproposal is required; Application submission is by invitation only. Application: October 22, 2014 11:59 p.m. Eastern time |

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|--|--|---|---|
| Therapeutic Idea Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-14-DMDRP-TIA | Principal Investigator: Investigator at all academic levels (or equivalent). | Supports early-stage, highrisk/high-reward research that leads to novel therapeutic development for DMD treatment. Innovation and impact are primary criteria. Studies should be hypothesis-based with a strong research strategy. Preliminary data are not required. | Maximum funding of \$300,000 in direct costs (plus indirect costs). Period of performance should not exceed 2 years. | Pre-application (Preproposal): July 16, 2014 5:00 p.m. Eastern time Preproposal is required; Application submission is by invitation only. Application: October 22, 2014 11:59 p.m. Eastern time |